Swedish Orphan Biovitrum AB (publ) Q2 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : And so I'll start with 2, and then get back in the queue. So I guess my question is on loncastuximab tesirine. So you're moving into oncology, which is, of course, quite different from benign haematology. So how are you preparing the commercial organization for this? I mean, what do you see as notable differences to your commercial approach in the existing markets? And can you tell us about any key competencies in oncology on the team already, and perhaps sort of what are key competitive differentiating attributes of ZYNLONTA versus other CD19 targeted products in development? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JULY 19, 2022 / 11:00AM, SOBIV.ST - Q2 2022 Swedish Orphan Biovitrum AB (publ) Earnings Call

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Yes, I'll get back in the queue.

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : So I guess the first question is, as the pricing of Elocta declines, the gross margin should, of course, be pressured to some degree. To what extent are there offsets to that? And then while we're talking about margins, can you quantify the potential margin impact pre and post reorganization, say, a couple of years out? I mean, is it more than a few tens of basis points?

Question: Christopher Winston Uhde - SEB, Research Division - Analyst : Okay. And then in terms of the R&D reorganization that Anders kind of summarized here this time, what could it mean in terms of, say, the average time to market saved or the number of indications that a product in-house could be expanded toward either for existing or pipeline medicines and also for pricing power?